Advaxis, Inc. 

(Public, OTC:ADXS)   Watch this stock   
Find more results for ADXS
Oct 29, 2009
ADVAXIS INC at The 8th Annual BIO Investor Forum - Webcast
  

Key stats and ratios

Q3 (Jul '09) 2008
Net profit margin - -8206.06%
Operating margin - -8260.61%
EBITD margin - -8100.00%
Return on average assets 42.93% -159.48%
Return on average equity - -315.89%
Employees 9 -

Address

Technology Center, New Jersey 675 Route 1, Suite 119
North Brunswick, NJ 08902
United States - Map
+1-732-5451590 (Phone)
+1-732-5451084 (Fax)

Website links

Advaxis, Inc. discussions

  View all discussions »

Description

Advaxis, Inc., formerly Great Expectations, Inc., is a development-stage biotechnology company focused on developing cancer vaccines that utilize mechanisms of immunity. The Company uses the Listeria system licensed from the University of Pennsylvania (Penn) to secrete a protein sequence containing a tumor-specific antigen. The Company has focused its initial development efforts upon cancer vaccines targeting cervical, head and neck, breast, prostate, and other cancers. Its products in development include Lovaxin C and Lovaxin B, Lovaxin P.

Officers and directors

Thomas A. Moore
Chairman of the Board, Chief Executive Officer
Age: 57
Fredrick D. Cobb
Principal Financial Officer, Vice President - Finance, Assistant Secretary
Age: 61
John Rothman Ph.D.
Executive Vice President - Clinical and Scientific Operations
Age: 60
James Patton
Director
Age: 51
Roni A. Appel
Director
Age: 41
Thomas McKearn
Director
Age: 57
Richard J. Berman
Director
Age: 66